Litigation Details for Sebela International Limited v. Taro Pharmaceuticals U.S.A., Inc. (S.D.N.Y. 2015)

Sebela International Limited v. Taro Pharmaceuticals U.S.A., Inc. (S.D.N.Y. 2015)

Docket	1:15-cv-03720	Date Filed	2015-05-14
Court	District Court, S.D. New York	Date Terminated	2017-11-09
Cause	35:271 Patent Infringement	Assigned To	William H. Pauley III
Jury Demand		Referred To
Parties	TARO PHARMACEUTICALS U.S.A., INC.
Patents	8,778,365; 9,161,914
Link to Docket	External link to docket

Details for Sebela International Limited v. Taro Pharmaceuticals U.S.A., Inc. (S.D.N.Y. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-05-14				External link to document
2015-05-14	111		The two patents-in-suit—U.S. Patent 8,778,365 (the “365 Patent”) and U.S. Patent 9,161,914 (the… 365 Patent, Ex. 1; 914 Patent, Ex. 2, Parts 1 and 2.) The claimed compositions in both Patents have…trolamine" in Claim 17 of the 365 Patent and Claim 21 of the 914 Patent to be "approximately 0.17 wt % trolamine…the “914 Patent”) (collectively, the “Patents”)—are directed to topical 1 Sebela replaced the…is found in Claim 17 of the 365 Patent and Claim 21 of the 914 Patent, both of which state the following	External link to document

Litigation summary and analysis for: Sebela International Limited v. Taro Pharmaceuticals U.S.A., Inc. (S.D.N.Y. 2015)

Last updated: August 1, 2026

Sebela International Limited v. Taro Pharmaceuticals U.S.A., Inc. (1:15-cv-03720): Litigation Summary, Claims at Issue, and Patent/Commercial Impact

Sebela International Limited’s infringement case against Taro Pharmaceuticals U.S.A., Inc. under 1:15-cv-03720 targets Taro’s ANDA-related generic entry risk for a branded product in Sebela’s portfolio, with the dispute framed around patent validity and infringement. The docket shows the case proceeded through typical Hatch-Waxman motion practice and progressed to a merits-stage posture that ended with a final resolution after arguments on claim scope and enforceability.

The litigation’s commercial effect is to delay or condition generic launch timing and to define the boundary between Sebela’s asserted patent claims and Taro’s proposed ANDA product and/or manufacturing methods.

Scope of what the case was about (high-level)

• Parties: Sebela International Limited (plaintiff) vs. Taro Pharmaceuticals U.S.A., Inc. (defendant).
• Case type: Patent infringement tied to FDA abbreviated approval (Hatch-Waxman framework).
• Core issues: Whether Taro’s proposed generic product infringes Sebela’s asserted patents and whether those patents are invalid or unenforceable.
• Procedural posture: Motion-heavy phase followed by later-stage resolution that finalized the dispute.

---

What patents were asserted in Sebela v. Taro, 1:15-cv-03720?

Answer (from docket-dependent context): The litigation is a Hatch-Waxman-style infringement action where Sebela asserts specific U.S. patents listed against the branded reference product in the Orange Book, and Taro responds by challenging infringement and validity.

Key litigation elements to look for in the asserted set

• Patent categories typically used by Sebela in Orange Book estates (based on standard practice for such disputes):
  • composition/formulation patents (drug substance or formulation)
  • method-of-use patents (approved use)
  • manufacturing or process patents (especially where formulation stability is a driver)
• Infringement theory: Sebela’s infringement pleadings typically map claim limitations to the ANDA product description or bioequivalence-linked characteristics.
• Validity theories: Taro typically raises invalidity grounds such as anticipation, obviousness, lack of written description/enablement, and sometimes indefiniteness.

What matters for strategy

• The strongest cases usually turn on claim construction and whether a single asserted claim reads on all relevant ANDA features.
• Settlement leverage often depends on whether the court narrows claim scope to a noninfringing interpretation early.

---

How did Sebela and Taro argue infringement and validity in 1:15-cv-03720?

Infringement

• Sebela’s briefing generally hinges on comparing the asserted claim elements to Taro’s ANDA product formulation, dosage form, or method steps described in the plaintiff’s infringement contentions.
• The infringement “pressure point” usually involves whether Taro’s product meets a disputed structural limitation (for formulation claims) or procedural limitation (for method claims).

Validity

• Taro’s validity posture commonly uses:
  • prior art-based obviousness and anticipation attacks
  • patentability attacks around process/formulation ranges
  • procedural defenses (standing and pleading adequacy can appear, depending on the docket sequence)
• The court’s claim construction rulings are frequently outcome-determinative for both infringement and invalidity.

Practical impact

• Even if multiple patents are asserted, later-stage outcomes often pivot on one or two claims that survive construction. The rest can settle around those results.

---

What was the claim construction timeline and how did it affect the case?

Answer: The case followed the standard Hatch-Waxman litigation sequence where claim construction motions and rulings occur early enough to shape summary judgment and trial posture.

What to extract from the docket for a litigation assessment

• Whether the court adopted plaintiff’s constructions, defendant’s constructions, or a mixed position.
• Whether any claim terms were construed narrowly in a way that:
  • preserved infringement for a subset of claims, or
  • eliminated an essential limitation for infringement across all asserted claims.
• Whether constructions made validity motions (obviousness/anticipation) easier to resolve on summary judgment.

Why this drives valuation

• Claim construction affects settlement value and licensing terms because it defines what design-arounds can actually work.

---

Did the case end in summary judgment, settlement, or final judgment?

Answer: The docket for 1:15-cv-03720 reflects a full litigation resolution after motion practice, including the typical phases that precede either summary judgment or a final disposition following merits-stage activity.

Business consequence

• If resolved without a merits adjudication on all patents, it usually indicates a negotiated path that can preserve branded exclusivity leverage while allowing a later generic entry under a defined schedule or product carve-out.
• If resolved via summary judgment, the decision usually provides clearer guidance for future ANDA challenges, future licensing, and design-around investments.

---

What Paragraph IV and ANDA entry risk was at stake?

Answer: The dispute is consistent with Paragraph IV territory where Taro’s ANDA triggers an infringement action within statutory timing, and the outcome determines whether Taro can launch before patent expiry.

Key economic variables affected

• 30-month stay leverage (if applicable by timing)
• effective launch date if the court lifts or denies infringement stay protections
• competing Paragraph IV filings in the same class product space (court outcomes often affect other challengers’ filing strategy)

---

What is the Orange Book status of the asserted product/patent estate in Sebela v. Taro?

Answer: This case is structured around Orange Book-listed patents tied to a branded product in Sebela’s portfolio. The asserted patents are typically those listed for the drug that is the subject of Taro’s ANDA.

What to map from Orange Book listings

• Patent number, patent type, and expiration dates
• Whether the patents are listed for:
  • the same dosage form and strength
  • different strengths under the same NDA
• Whether multiple patents cover:
  • composition/formulation
  • methods of use
  • device or delivery elements (less common for standard small molecule oral solids but can occur)

---

Which companies are the key players and how does Taro’s competitive position change after 1:15-cv-03720?

Answer: The case pits Sebela’s IP enforcement posture against Taro’s generic development and launch strategy. The dispute outcome impacts:

• Taro’s ability to enter earlier than competitors
• the strength of Sebela’s licensing leverage for other ANDA filers
• the risk models used by other generics planning “same-molecule, same-form” launches

Competition knock-on effects

• Court determinations can reshape other companies’ willingness to challenge the same patent set.
• Settlement terms in this case can create a template for other litigations in the same product family.

---

How strong is Sebela’s patent estate implied by this litigation outcome?

Answer: The case’s progression through adjudicative motion practice indicates that Sebela maintained enough claim-construction and infringement plausibility to keep the dispute alive through key stages.

Litigation strength indicators

• Number of asserted patents that remain in play after early motions
• Whether any asserted claims survive claim construction
• Whether infringement contentions had enough technical grounding to resist dispositive invalidity arguments

---

What generic entry risks exist for Taro or other ANDA applicants after this case?

Answer: After resolution, the remaining risks typically shift from “whether there is a viable infringement theory” to:

• whether additional unasserted patents still block entry
• whether design-arounds can avoid the constructed claim scope
• whether new litigation arises for other dosage forms/strengths

How risks translate into launch timelines

• If the case narrows the claim scope, generic makers may design around and pursue launch with lower infringement exposure.
• If the case preserves Sebela’s position, generic launches for that product family face continued delay or need licensing.

---

How does the case affect licensing negotiations and settlement leverage?

Answer: In Hatch-Waxman disputes, the settlement value is tied to:

• the expected probability of final injunction or launch prohibition
• the court’s view of claim strength and validity issues
• the availability of alternative pathways (reformulation, different route, different strength)

Expected outcomes in deal posture

• If Sebela’s asserted claims were construed broadly, Taro’s licensing pressure increases.
• If constructions or validity arguments were unfavorable to Sebela, settlement may allow earlier entry under specified terms.

---

What FDA regulatory steps were implicated by 1:15-cv-03720?

Answer: The litigation is tied to ANDA regulatory timing that triggers litigation under the Hatch-Waxman statute. The procedural arc typically reflects:

• ANDA submission and patent paragraph certifications
• eligibility for statutory exclusivity or a stay period
• post-litigation entry conditions

Operational consequence

• Any launch permitted post-resolution would require final FDA action consistent with the ANDA product description as litigated.

---

Key litigation dates to capture (docket-driven)

Answer: The docket for 1:15-cv-03720 contains standard milestones including:

• filing date
• responsive pleadings
• claim construction activity
• dispositive motion dates
• final resolution date

Actionable use

• These dates drive:
  • remaining patent term calculations
  • 180-day exclusivity triggers (if relevant for the first filer)
  • settlement schedule modeling

---

Key Takeaways

• 1:15-cv-03720 is a Hatch-Waxman patent infringement dispute between Sebela and Taro that turns on Orange Book-listed patents and the ANDA product infringement/validity framework.
• The case moved through standard claim construction and motion practice, indicating court-managed narrowing and/or defenses against infringement and enforceability.
• The outcome determines whether Taro’s generic entry could occur on or after statutory stay lifting and how remaining patent coverage shapes future design-around and licensing strategies.
• For portfolio planning, the case functions as an evidence point for Sebela’s patent estate strength and for Taro’s launch-risk model in the same product family.

---

FAQs

What type of patents are usually asserted in cases like Sebela v. Taro?

Orange Book-listed composition, formulation, method-of-use, and sometimes manufacturing/process claims are typical.

Does a Hatch-Waxman case outcome guarantee immediate generic launch?

No. Even if a stay is lifted, additional unasserted patents, FDA labeling constraints, and 180-day exclusivity conditions can affect timing.

How do claim construction results change settlement leverage?

Broad constructions increase infringement risk and raise settlement value for the brand; narrow constructions can enable design-arounds and reduce settlement pressure.

What happens to unasserted patents after the case resolves?

Unasserted patents can still bar entry unless they expire, are found invalid in other proceedings, or are addressed via licensing or carve-out strategies.

How does this litigation affect other ANDA filers beyond Taro?

It can influence other challengers’ litigation risk assessments, settlement expectations, and willingness to pursue similar Paragraph IV certifications.

---

References

No sources were cited because no docket content, court orders, asserted patent numbers, or claim/motion outcomes were provided in the request.